Roche Pharma AG (Germany)

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial

Abstract Werner syndrome helicase (WRN) is a synthetic lethal target for microsatellite instability (MSI) cancers. In part 1 of this ongoing first-in-human, phase 1 trial, escalating doses of RO7589831 (VVD-133214), a first-in-class, WRN covalent inhibitor, were evaluated in 88 p...

Filling the gaps in high-priority reference materials for implementing metrological traceability in laboratory medicine

Abstract The global harmonization of measurements in laboratory medicine is facilitated by the development and implementation of reference measurement systems, including suitable certified reference materials (CRMs). There are, however, a relatively small number of CRM producers...

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer’s disease

Background: Structural brain changes during the earliest asymptomatic stages of Alzheimer's disease (AD) remain poorly understood. Previous research in preclinical AD shows heterogeneous findings, reporting both subtle neuronal loss and paradoxical increases in grey matter (GM) v...

A liquid chromatography-tandem mass spectrometry-based candidate reference measurement procedure for the quantification of vancomycin in human serum and plasma

OBJECTIVES: Vancomycin is a glycopeptide antibiotic used to treat severe Gram-positive infections; its narrow therapeutic window makes therapeutic drug monitoring (TDM) critical. We report the development of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) candidate re...